CLOs on the Move

Arvinas

www.arvinas.com

 
Arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as PROTACs (PROteolysis TArgeting Chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. This greatly expands the ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.arvinas.com
  • 5 Science Park 395 Winchester Avenue
    New Haven, CT USA 06511
  • Phone: 203.535.1456

Executives

Name Title Contact Details
Christina Bailey
Associate General Counsel Profile
Paul McInulty
Senior Vice President, Regulatory Affairs Profile
Jared Freedberg
General Counsel and Corporate Secretary Profile

Similar Companies

Merck KGAA

Merck KGAA is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tranquis Therapeutics

Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide.

Foxtag Enterprises

Foxtag Enterprises is a Rockledge, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rentschler Biopharma United States

What unites us at Rentschler Biopharma, is the passion for what we do. As a full-service CDMO we are your outsourcing partner for the bioprocess development, cGMP manufacturing and aseptic filling of biopharmaceuticals as well as for the elaboration of approval strategies for your products. Thanks to our many years of experience, the quality of our associated consulting activities, and our expertise in finding solutions, we are among the top suppliers in our field. Founded in 1927, Rentschler is a family owned and independent company. Our company structure guarantees rapid decision-making and efficient, smooth-running processes, and consequently keeping project timelines. Already in the early beginnings of biotechnology, Rentschler has built up a reputation with the development of different Interferon products (Fiblaferon, Polyferon). Nowadays, our attention is firmly focused on your products. For the success of your project we can refer to our experience in various molecules like antibodies, fusion proteins or enzymes. Thanks to our focus on innovations, we are always on the cutting edge of technologies.

Nurix Therapeutics

Nurix Therapeutics discovers drugs that harness the body`s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.